Chester County News and Community Website
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported second-quarter financial results and provided a detailed business update, emphasizing progress toward a 2027 Biologics License Application (BLA) submission for its lead …
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has unveiled new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. The findings highlight potential breakthroughs for rese-cel …
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced the pricing of its underwritten public offering, aiming to raise approximately $100 million in gross proceeds. The offering comprises 39,200,000 …
Cabaletta Bio Prices Public Offering to Raise $100 Million Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced today it has started an underwritten public offering of common stock and accompanying warrants (or pre-funded warrants in lieu of common …
Cabaletta Bio Announces Public Offering of Common Stock and Warrants Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in …
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced key updates on its RESET-Myositis trial and plans for the anticipated 2027 Biologics License Application (BLA) submission for rese-cel (resecabtagene …
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full year 2024, along with significant updates across its clinical programs. The company, …
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled to take place on Monday, March 3, 2025, …
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated …
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy Read More PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two prominent scientific conferences this …
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences Read More